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Defective Presynaptic Choline Transport
Underlies Hereditary Motor Neuropathy
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The neuromuscular junction (NMJ) is a specialized synapse with a complexmolecular architecture that provides for reliable transmission
between the nerve terminal and muscle fiber. Using linkage analysis and whole-exome sequencing of DNA samples from subjects with
distal hereditary motor neuropathy type VII, we identified a mutation in SLC5A7, which encodes the presynaptic choline transporter
(CHT), a critical determinant of synaptic acetylcholine synthesis and release at the NMJ. This dominantly segregating SLC5A7mutation
truncates the encoded product just beyond the final transmembrane domain, eliminating cytosolic-C-terminus sequences known to
regulate surface transporter trafficking. Choline-transport assays in both transfected cells and monocytes from affected individuals
revealed significant reductions in hemicholinium-3-sensitive choline uptake, a finding consistent with a dominant-negative mode of
action. The discovery of CHT dysfunction underlying motor neuropathy identifies a biological basis for this group of conditions and
widens the spectrum of disorders that derive from impaired NMJ transmission. Our findings compel consideration of mutations in
SLC5A7 or its functional partners in relation to unexplained motor neuronopathies.The distal hereditary motor neuronopathies (dHMNs)
comprise a heterogeneous group of diseases that share
a common feature of a length-dependent neuropathy re-
sulting in progressive distal muscle wasting and weakness.
Electrophysiology and electromyography (EMG) studies
have revealed normal motor and sensory conduction
velocities with reduced compound-motor-action-potential
amplitudes and neurogenic changes, suggesting that
pathology is at the level of the anterior horn cell. Harding
described seven subtypes of dHMNs on the basis of clinical
and genetic criteria.1 Isolation of the causative genes in the
dominant forms of dHMNs has revealed genetic heteroge-
neity within subtypes, and mutations in six genes have
been described to date and include DCTN1 (MIM
601143), GARS (MIM 600287), BSCL2 (MIM 606168),
HSPB8 (MIM 608041), HSPB1 (MIM 602195), and HSPB3
(MIM 604624). These findings implicate processes such
as protein misfolding, RNA metabolism, and axonal trans-
port as pathologic mechanisms in this disorder.2 Several of
these genes also cause forms of Charcot-Marie-Tooth
disease type 2 (CMT2), which is categorized separately on
the basis of sensory-nerve involvement.
We previously detailed the clinical features of members
of a large UK family affected by dominantly transmitted
dHMN type VII (dHMN-VII [MIM 158580]), distinguished
by the presence of vocal-cord involvement in affected
subjects, and we mapped the gene responsible to chromo-
somal region 2q14.3–5 Here, we report the identification of
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choline transporter (CHT), a critical determinant of
synaptic acetylcholine (ACh) synthesis and release at the
neuromuscular junction (NMJ). Mutations affecting genes
coding for NMJ proteins arewell known to cause a contrast-
ing phenotype of congenital myasthenic syndrome, which
is characterized by fatiguing muscle weakness and cranial-
nerve and respiratory-muscle involvement.6 Our findings
are thus unexpected and widen the phenotypical spectrum
associated with NMJ dysfunction.
Our studies derive from the analysis of samples from 26
family members (14 affected and 12 unaffected) obtained
with informed consent; the research protocol was
approved by the Wandsworth Local Research Ethics
Committee. In order to identify the disease-associated
gene, we performed whole-exome sequencing of a single
affected individual (VI:5) in this family (Figure 1). Coding
regions were captured with SureSelect All Exons (50 Mb)
and sequenced by Illumina HiSeq, yielding 9.8 Gb data
(~130 million reads) corresponding to 91% target coverage
with a mean depth of 1073 and identifying 52,806 vari-
ants (Tables S2 and S3, available online). After filtering,
only one probably deleterious variant was identified
within the critical region; this was a single base deletion
(c.1497delG) in SLC5A7 (RefSeq accession number
NM_021815.2), encoding the Naþ/Cl dependent, high-
affinity CHT7–9 (Figure S1). Dideoxy sequence analysis, as
well as Ssp1 restriction digestion (Figure 1), confirmed
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Figure 1. Family Pedigree and c.1497delG Cosegregation
The c.1497delG variant results in the creation of a novel SspI restriction site that facilitates cosegregation analysis by restriction digestion
of exon 9 PCR products resolved by polyacrylamide gel electrophoresis (PCR primers used for amplification of genomic DNA were
50-CCCTGGCTATTACCCTGATG-30 and 50-CACAAGTGCAAGTTCATCTAATTT-30). The c.1497delG variant results in the digestion of
the WT 218 bp product into fragments of 198 bp and 20 bp (not shown). All subjects with the 198 bp fragment are heterozygous
and thus also have an undigested 218 bp band. These genotypings were also confirmed by dideoxy sequence analysis. For cross reference
with the previously published pedigree, refer to Table S1.and the variant was found to be present in monocyte
mRNA of the affected cases (not shown). The variant is
not present in genomic databases or 150 UK control indi-
viduals. Three other unrelated individuals, who each had
dHMN-VII-like features involving some degree of distal
muscle wasting and vocal-cord paralysis, were investigated
for SLC5A7 mutations; TRPV4 (MIM 605427) mutations,
which might phenotypically overlap with mutations
causing dHMN-VII, were previously excluded in each
case. This revealed no other novel sequence variants, indi-
cating that the individuals investigated might possess
a clinically distinct condition or that there exists further
genetic heterogeneity in this very rare condition.
The c.1497delG nucleotide change is predicted to result
in a translational frameshift (FS) changing Lys499 to Asn
and to then encode an additional 11 ectopic amino acids
prior to a premature stop codon (p.Lys499Asnfs*13). This
alteration results in elimination of the transporter’s final
82 amino acids, entailing a near complete deletion of the
transporter’s cytoplasmic C terminus (Figure S2). Because
the C terminus displays strong sequence conservation
across many species (Figure S2) and encodes residues
known to regulate surface trafficking,10 loss of this domain
is likely to have profound functional consequences.
We investigated the functional impact of the c.1497delG
variant via heterologous expression of cDNAs encoding
mutant (FS) and wild-type (WT) CHT in transiently-
transfected human embryonic kidney (HEK) 293 cells.
Existing antibodies against CHT target the transporter’s
C terminus,11 precluding their use in characterizing FS
CHT. Thus, in order to detect WT and FS CHT, we added1104 The American Journal of Human Genetics 91, 1103–1107, Decea hemagluttinin (HA) tag to the N termini of both trans-
porters by using site-directed mutagenesis (Quick-Change
kit, Stratagene). Cell-surface biotinylation experiments
were performed as previously described.12 WT CHT
migrated in transiently transfected HEK 293 cells as two
broad bands of 48 kDa and 56 kDa; the 48 kDa band repre-
sents an immature, core-glycosylated species, and the
56 kDa band represents the mature, more highly glycosy-
lated species that is enriched at the cell surface11
(Figure 2A). For equivalent amounts of transfected cDNA,
reduced levels of both 48 kDa and 56 kDa products were
observed, suggesting a reduced translation or stability of
FS CHT. Doubling the amount of transfected transporter
cDNAs produced a comparable increase in WT and FS
CHT, maintaining their relative differences in protein
level. Saturation analysis of [3H]-choline transport in FS-
CHT-transfected cells demonstrated a significant reduction
in transport activity relative to that inWT-CHT-transfected
cells; this reduction was accounted for by a decrease in
choline transport VMAX as opposed to a change in choline
KM (Figure 2B). To determine whether the reduction in FS-
CHT transport VMAX arises from a change in surface-CHT
levels, we labeled cell-surface proteins with a membrane-
impermeant biotinylating reagent and followed this with
purification on Streptavidin beads, SDS-PAGE of total and
surface extracts, and immunoblotting for the HA tag. As
noted previously, two forms of WT and FS CHT were de-
tected, and the mature, more substantially glycosylated
form was enriched in cell-surface extracts (Figure 2C).
Importantly, when the two transporter cDNAs were coex-
pressed (cDNA levels equal to 13 in Figure 2A), thember 7, 2012
Figure 2. Immunoblotting and Cell-
Surface Biotinylation of WT and FS CHT
(A) Levels of total WT and FS CHT after
SDS-PAGE and immmunoblotting with
HA antibody confirm FS-CHT truncation
and reveal reduced expression of total FS
CHT at both 23 (lanes 1 and 2) and 13
(lanes 3 and 4) protein. Stripping and blot-
ting for b-actin reveal equal protein loaded
across lanes. All experiments were con-
ducted with the same total amount of
transfected plasmid and were balanced
with a pcDNA3 vector.
(B) Saturation analysis of HC-3-sensitive
choline-transport activity in transfected
HEK 293 cells demonstrates significantly
reduced transport activity for FS CHT
than for WT CHT. Transport deficits of
FS-CHT-transfected wells are accounted
for by a reduction in choline transport
VMAX (33.4% reduction, p ¼ 0.024,
Student’s unpaired t test) as opposed to
a change in choline KM (WT ¼ 5.15 5
1.12 mM, FS ¼ 6.12 5 1.72 mM, p ¼ 0.66,
Student’s unpaired t test). Specific choline
uptake was determined by subtraction of
the uptake obtained from transfected cells
from that obtained from mock (vector)
transfected cells acquired from assays con-
ducted in parallel.
(C) Levels of total and surface WT and FS
CHT are lower in cells transfected with
both WT and FS CHT at 13 levels (as
presented in A) than in cells separately transfected at 13 levels. All transfections were performed with identical amounts of total
plasmid and were balanced by a pcDNA3 vector. Equivalent findings were obtained with cells transfected with the tagged WT and FS
CHT constructs.
(D) Choline-transport activity is lower in FS CHT than in WT CHT (n ¼ 5, *p ¼ 0.035, Student’s unpaired t test). Observed transport
activity of cells coexpressing WT and FS CHT (WT þ FS(o)) falls significantly below that expected (WT þ FS(e)) from a sum of the inde-
pendent expression of these isoforms (n ¼ 5,*p ¼ 0.005, Student’s unpaired t test).
(E) HC-3-sensitive choline-transport activity in whole-blood monocytes of dHMN-VII subjects (n ¼ 4) and controls (n ¼ 11) reveals
a dramatic loss in dHMN-VII subjects (*p ¼ 0.72 3 106, Student’s one-tailed t test).combined levels of surface transporters of the two isoforms
were reduced to ~30% of that calculated from a simple
addition of levels when the two cDNAs were transfected
individually (Figure 2C; Student’s unpaired t test, p ¼
0.001, n¼ 5). These studies indicate that the FS CHTexerts
a dominant-negative impact on total- and surface-protein
levels, whether blotting for WT or FS CHT. Consistent
with this finding, CHT activity in cells coexpressing WT
and FS CHT constructs was found to be reduced signifi-
cantly below that expected from a summation of transport
activities from cells independently transfected with cDNA
encoding either WT or FS CHT (Figure 2D). Notably,
activity seen with dual transfection was even lower than
observed when cells were transfected with FS-CHT-encod-
ing cDNA, revealing that a more severe impact arises
when cells produce CHTs with mismatched C termini.
To investigate whether a similar reduction in CHT
activity might be present in patient cells that natively
express both mutant and WT SLC5A7 transcripts, we
measured choline transport in whole-blood monocytes
obtained from affected subjects and control individuals
by using previously described methods.8 In these experi-
ments, we readily detected HC-3-sensitive choline-trans-The American Jouport activity in cells from control subjects (Figure 2E). In
contrast, choline-transport activity in cells from individ-
uals with the c.1497delG SLC5A7 variant was barely detec-
tible, consistent with the minimal transport activity
observed in cells transfected with cDNAs encoding both
WT and FS CHT. Together, these findings provide strong
evidence for a dominant-negative impact of the p.Ly-
s499Asnfs*13 alteration as opposed to effects expected
from haploinsufficiency alone.
CHT is enriched inmotor neurons and nerve terminals11
and is essential for NMJ signaling,13,14 providing a strong
impetus for further evaluation of the structural and func-
tional impact of the CHT variant. The NMJ is a specialized
synapse designed to faithfully transmit electrical impulses
from the presynaptic nerve terminal of the motor neuron
to postsynaptic muscle cells via ACh. The genetically
heterogeneous neuromuscular disorders known as the
congenital myasthenic syndromes (CMSs) are well recog-
nized to result from mutations in genes encoding presyn-
aptic, postsynaptic, and synaptic NMJ proteins. Key
characteristics of CMSs include fatiguing muscle weakness
with a pathological decrement on repetitive muscle stimu-
lation or abnormal jitter and blocking on single-fiber EMG.rnal of Human Genetics 91, 1103–1107, December 7, 2012 1105
Onset of CMSs is typically congenital, and ophthalmopa-
resis, ptosis, and bulbar weakness are frequently seen. In
contrast, onset of dHMN-VII is generally in the end of
the first decade or in the middle of the second decade
and occurs with a nonfatiguing progressive distal muscle
wasting and weakness in association with vocal-cord paral-
ysis due to involvement of the tenth cranial nerve (VCP;
Table S4). The lack of a CMS phenotype in dHMN-VII
subjects was unexpected and prompted us to repeat the
electrophysiology studies in two affected subjects (V:19
[male, 56 years old] and VI:12 [male, 28 years old]) from
the family (Figure 1). Repetitive stimulation showed no
significant decrement, and the fact that single-fiber EMG
showed an excess of jitter and blocking is suggestive of
a disturbance of NMJ function (data not shown), but
such changes could also be secondary to reinnervation.
The changes were less marked in the younger of the two
subjects (the disease in this subject progressed less).
Approximately 5% of molecularly characterized CMS indi-
viduals are associated with defects in choline acetyltrans-
ferase (encoded by CHAT [MIM 118490]), the enzyme
responsible for ACh synthesis, whereas the majority have
defects in postsynaptic nicotinic ACh receptors (AChRs)
rapsyn (encoded by RAPSN [MIM 601592]) or DOK7 (en-
coded by DOK7 [MIM 610285]).15–19
Although the phenotype associated with mutations in
these genes differs significantly from that of dHMN-VII,
it is noteworthy that vocal-cord paresis, frequently pre-
senting as congenital stridor, is a feature of CMS particu-
larly in association with DOK7mutations and occasionally
with mutations in CHAT.20,21 Possibly, this observation
might be coincidental; however, the differences between
dHMN-VII and CMS might relate to the unique contribu-
tion that CHT and the protein products of the CMS-associ-
ated genes make to cholinergic signaling in the context of
the demands of different neuromuscular synapses. CHT is
present (so far as is known) at all cholinergic synapses, but
NMJs exhibit structural and functional variation across
species, as well as between muscle-fiber types.22 Two forms
of NMJs are known: (1) ‘‘en plaque,’’ where themuscle fiber
has a single innervation and an NMJ diameter of 50 mm
and (2) ’’en grappe,’’ where the muscle fiber receives
multiple synaptic contacts at NMJs of 10–16 mm in diam-
eter. En grappe synapses innervate tonic fibers that are
present on only a small number of mammalian muscle
fibers and have been shown to release ACh by almost an
order of magnitude longer than twitch terminals. En
grappe NMJs are present on extraocular, stapedius, tensor
tympani, laryngeal, and tongue muscle fibers. Evidence
supports a role for CHT primarily in sustained, high-
frequency ACh signaling23 given that reserve ACh stores
are available for sustaining low-frequency signaling24 and
because choline can be acquired through other mecha-
nisms, such as the transporters that maintain choline
phospholipid synthesis in all cells. Consequently, it is
possible that the synapses affected in dHMN-VII are more
dependent on CHT as a result of a requirement for1106 The American Journal of Human Genetics 91, 1103–1107, Decesustained, high-frequency ACh release. Indeed, model-
system studies withHC-3 have demonstrated a suppression
of ACh release and cholinergic signaling only with sus-
tained or higher-frequency stimulation.23 Alternatively,
these synapses might be more sensitive to reduced CHT
levels than are synapses with higher CHT levels. Structural
and physiological differences exist among singly inner-
vated fibers, where fast-twitch fibers display greater
quantal release than do slow-twitch fibers, and thus the
proportion of fibers within the affected motor systems
might contribute sensitivity to the loss of CHT as well.
Furthermore, unaffected neurons might also be protected
by CTL1, a low-affinity CHT that has been reported to be
present in motor neurons in rodents25 and to exhibit
differential expression patterns across different NMJs.
Slc5a7-knockout mice display early postnatal paralysis,
cyanosis, and lethality.13 Because a dominant-negative
impactof the c.1497delGvariantdoesnotpreclude thepres-
enceof a lowamountof choline transport andbecause respi-
ratory rates are much higher in mice than in humans, the
lack of early-onset paralysis and respiratory dysfunction in
our dHMN-VII-affected individualsmightnot be surprising.
The deficits of our dHMN-VII subjects are more severe than
they are in hemizygous Slc5a7 mice that are viable and do
not exhibit an age-dependent motor neuropathy, although
these animals do exhibit reducedCNSand autonomic levels
of ACh and enhanced exercise-induced fatigue.26 Because
NMJ morphology is altered in Slc5a7-knockout mice and
shows similar alterations in Chat-knockout mice,27 the
delayed nature of symptoms might also arise from differ-
ences in terminal plasticity that responds to reduced cholin-
ergic signaling. This aspect might be illuminated by the
assessment of NMJ morphology in the affected endplates
of individuals with dHMN-VII and in studies of FS-Slc5a7
knockin transgenic models.
In summary, we provide genetic and functional evi-
dence that dominantly acting SLC5A7 mutations underlie
dHMN-VII, raising the possibility that CHT might have
a role in idiopathic motor neuronopathies. Knowledge of
amolecular lesionunderlying dHMN-VII provides a genetic
test for disease risk in affected families andmight permit the
development of rational pharmacotherapies. Furthermore,
CHT or its regulation should be considered as a potential
contributor to idiopathic motor neuronopathies.Supplemental Data
Supplemental Data include two figures and four tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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